Neurocrine Biosciences
NBIX
418 hedge funds and large institutions have $11.1B invested in Neurocrine Biosciences in 2020 Q2 according to their latest regulatory filings, with 89 funds opening new positions, 169 increasing their positions, 112 reducing their positions, and 36 closing their positions.
147% more first-time investments, than exits
New positions opened: 89 | Existing positions closed: 36
51% more repeat investments, than reductions
Existing positions increased: 169 | Existing positions reduced: 112
41% more capital invested
Capital invested by funds: $7.91B → $11.1B (+$3.23B)
14% more funds holding
Funds holding: 368 → 418 (+50)
9% more call options, than puts
Call options by funds: $71.2M | Put options by funds: $65.4M
0.78% less ownership
Funds ownership: 98.95% → 98.17% (-0.78%)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$120M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$106M |
| 3 |
Renaissance Technologies
New York
|
+$84.6M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$74.9M |
| 5 |
BlackRock
New York
|
+$60.9M |
Top Sellers
| 1 |
HM
HealthCor Management
New York
|
-$132M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$125M |
| 3 |
PA
Perceptive Advisors
New York
|
-$102M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$94.2M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$55.6M |
NBIX Hedge Fund Activity: Q2 2020 in Review
418 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q2 2020, worth a combined $11.1B — up 41% from $7.91B a quarter earlier.
Buyers outnumbered sellers: 89 funds opened new NBIX positions and 36 closed out — a net gain of 53 holders — while 169 added to existing stakes and 112 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $120M. The largest seller was HealthCor Management, cutting an estimated $132M.
- 418 institutional investors held Neurocrine Biosciences (NBIX) as of Q2 2020, up from 368 in Q1 2020.
- Funds reported $11.1B of Neurocrine Biosciences stock for Q2 2020, up 41% quarter-over-quarter.
- 89 funds opened new Neurocrine Biosciences positions in Q2 2020 and 36 closed out, a net change of +53 holders.
- The largest Neurocrine Biosciences buyer in Q2 2020 was Fidelity Investments, an estimated $120M added.
- The largest Neurocrine Biosciences seller in Q2 2020 was HealthCor Management, an estimated $132M sold.
Based on aggregated 13F filings for Q2 2020.